LongTVTXJun 2026
Travere Therapeutics, Inc.
Travere Therapeutics specialises in treatments for rare kidney and metabolic disorders. Its foundational drug was recently approved for an additional kidney disease, expanding…
TVTX
Which hedge funds are long TVTX?
2 published ideas on Travere Therapeutics, Inc. across 2 funds — 2 long and 0 short.
Travere Therapeutics hedge fund investment theses
Each stock pitch below comes from a fund manager's own investor letter, not a 13F filing, so it carries the reasoning behind the portfolio position on Travere Therapeutics: the full investment thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.
Funds with a position view
Long theses
LongTVTXJun 2026
Travere Therapeutics Inc.
Travere Therapeutics recovered after an earlier regulatory setback and received FDA approval for FILSPARI in focal segmental glomerulosclerosis during the quarter. The approval…